142 related articles for article (PubMed ID: 36094651)
1. IL-2/IL-2R signaling and IL-2Rα-targeted therapy in anaplastic large cell lymphoma.
Liang HC
Pathologie (Heidelb); 2022 Aug; 43(Suppl 1):25-30. PubMed ID: 36094651
[TBL] [Abstract][Full Text] [Related]
2. Super-enhancer-based identification of a BATF3/IL-2R-module reveals vulnerabilities in anaplastic large cell lymphoma.
Liang HC; Costanza M; Prutsch N; Zimmerman MW; Gurnhofer E; Montes-Mojarro IA; Abraham BJ; Prokoph N; Stoiber S; Tangermann S; Lobello C; Oppelt J; Anagnostopoulos I; Hielscher T; Pervez S; Klapper W; Zammarchi F; Silva DA; Garcia KC; Baker D; Janz M; Schleussner N; Fend F; Pospíšilová Š; Janiková A; Wallwitz J; Stoiber D; Simonitsch-Klupp I; Cerroni L; Pileri S; de Leval L; Sibon D; Fataccioli V; Gaulard P; Assaf C; Knörr F; Damm-Welk C; Woessmann W; Turner SD; Look AT; Mathas S; Kenner L; Merkel O
Nat Commun; 2021 Sep; 12(1):5577. PubMed ID: 34552066
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation.
Merkel O; Hamacher F; Griessl R; Grabner L; Schiefer AI; Prutsch N; Baer C; Egger G; Schlederer M; Krenn PW; Hartmann TN; Simonitsch-Klupp I; Plass C; Staber PB; Moriggl R; Turner SD; Greil R; Kenner L
J Pathol; 2015 Aug; 236(4):445-56. PubMed ID: 25820993
[TBL] [Abstract][Full Text] [Related]
4. PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas.
Laimer D; Dolznig H; Kollmann K; Vesely PW; Schlederer M; Merkel O; Schiefer AI; Hassler MR; Heider S; Amenitsch L; Thallinger C; Staber PB; Simonitsch-Klupp I; Artaker M; Lagger S; Turner SD; Pileri S; Piccaluga PP; Valent P; Messana K; Landra I; Weichhart T; Knapp S; Shehata M; Todaro M; Sexl V; Höfler G; Piva R; Medico E; Ruggeri BA; Cheng M; Eferl R; Egger G; Penninger JM; Jaeger U; Moriggl R; Inghirami G; Kenner L
Nat Med; 2012 Nov; 18(11):1699-704. PubMed ID: 23064464
[TBL] [Abstract][Full Text] [Related]
5. An oncogenic axis of STAT-mediated BATF3 upregulation causing MYC activity in classical Hodgkin lymphoma and anaplastic large cell lymphoma.
Lollies A; Hartmann S; Schneider M; Bracht T; Weiß AL; Arnolds J; Klein-Hitpass L; Sitek B; Hansmann ML; Küppers R; Weniger MA
Leukemia; 2018 Jan; 32(1):92-101. PubMed ID: 28659618
[TBL] [Abstract][Full Text] [Related]
6. Complete response in a critically ill patient with ALK-negative anaplastic large cell lymphoma treated with single agent brentuximab-vedotin.
Oregel KZ; Everett E; Zhang X; Nagaraj G
Expert Rev Anticancer Ther; 2016; 16(3):279-83. PubMed ID: 26809026
[TBL] [Abstract][Full Text] [Related]
7. Analysis and therapeutic targeting of the IL-1R pathway in anaplastic large cell lymphoma.
Song Z; Wu W; Wei W; Xiao W; Lei M; Cai KQ; Huang DW; Jeong S; Zhang JP; Wang H; Kadin ME; Waldmann TA; Staudt LM; Nakagawa M; Yang Y
Blood; 2023 Oct; 142(15):1297-1311. PubMed ID: 37339580
[TBL] [Abstract][Full Text] [Related]
8. Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease.
Eyre TA; Khan D; Hall GW; Collins GP
Eur J Haematol; 2014 Dec; 93(6):455-68. PubMed ID: 24766435
[TBL] [Abstract][Full Text] [Related]
9. Brentuximab vedotin and crizotinib in anaplastic large-cell lymphoma.
Foyil KV; Bartlett NL
Cancer J; 2012; 18(5):450-6. PubMed ID: 23006951
[TBL] [Abstract][Full Text] [Related]
10. Beyond NPM-anaplastic lymphoma kinase driven lymphomagenesis: alternative drivers in anaplastic large cell lymphoma.
Tabbò F; Ponzoni M; Rabadan R; Bertoni F; Inghirami G;
Curr Opin Hematol; 2013 Jul; 20(4):374-81. PubMed ID: 23673339
[TBL] [Abstract][Full Text] [Related]
11. Anaplastic large cell lymphoma, ALK-negative.
Ferreri AJ; Govi S; Pileri SA; Savage KJ
Crit Rev Oncol Hematol; 2013 Feb; 85(2):206-15. PubMed ID: 22789917
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis and management of ALK-positive anaplastic large cell lymphoma in children and adolescents.
Rigaud C; Knörr F; Brugières L; Woessmann W
Best Pract Res Clin Haematol; 2023 Mar; 36(1):101444. PubMed ID: 36907641
[TBL] [Abstract][Full Text] [Related]
13. ALK expression plays different roles in anaplastic large-cell lymphomas and outcome of crizotinib use in relapsed/refractory ALK+ patients in a Chinese population.
Huang L; Zhang F; Zeng J; Guo H; Liu S; Wei X; Chen F; Jiang X; Liang Z; Liu Y; Li W
Ann Hematol; 2018 Jan; 97(1):149-159. PubMed ID: 29150811
[TBL] [Abstract][Full Text] [Related]
14. The biology and management of systemic anaplastic large cell lymphoma.
Hapgood G; Savage KJ
Blood; 2015 Jul; 126(1):17-25. PubMed ID: 25869285
[TBL] [Abstract][Full Text] [Related]
15. Leukaemic relapse of anaplastic large cell lymphoma, ALK negative.
Karki NR; Badin K; Savage N; Bryan L
BMJ Case Rep; 2021 Feb; 14(2):. PubMed ID: 33619137
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma.
Gao J; Yin M; Zhu Y; Gu L; Zhang Y; Li Q; Jia C; Ma Z
BMC Cancer; 2013 Oct; 13():471. PubMed ID: 24112608
[TBL] [Abstract][Full Text] [Related]
17. [Expressions and clinical significance of GAS1, IL-1RAP and PRF1 in patients with ALK positive anaplastic large cell lymphoma].
Jiang Y; Cao D; Xu CG
Zhonghua Xue Ye Xue Za Zhi; 2018 Feb; 39(2):116-121. PubMed ID: 29562445
[No Abstract] [Full Text] [Related]
18. Anaplastic Large Cell Lymphoma: Contemporary Concepts and Optimal Management.
Shustov A; Soma L
Cancer Treat Res; 2019; 176():127-144. PubMed ID: 30596216
[TBL] [Abstract][Full Text] [Related]
19. IL-21 contributes to JAK3/STAT3 activation and promotes cell growth in ALK-positive anaplastic large cell lymphoma.
Dien Bard J; Gelebart P; Anand M; Zak Z; Hegazy SA; Amin HM; Lai R
Am J Pathol; 2009 Aug; 175(2):825-34. PubMed ID: 19608866
[TBL] [Abstract][Full Text] [Related]
20. Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations.
Chen J; Zhang Y; Petrus MN; Xiao W; Nicolae A; Raffeld M; Pittaluga S; Bamford RN; Nakagawa M; Ouyang ST; Epstein AL; Kadin ME; Del Mistro A; Woessner R; Jaffe ES; Waldmann TA
Proc Natl Acad Sci U S A; 2017 Apr; 114(15):3975-3980. PubMed ID: 28356514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
